If you have been treated with ANCA vasculitis and you are now in remission, you may be able to participate in a study to test if a specific blood test can help your doctor decide if you need maintenance therapy.

This study consists of two online surveys and one laboratory visit on the UNC campus. Plus, a subset of participants will be randomized to make small shifts in their daily behaviors for 35 consecutive days and all participants will complete brief nightly surveys during that 35-day phase. Some participants will also watch a short, 10 minute video.

Have you been diagnosed with multiple myeloma or high-risk smoldering multiple myeloma? If so, you may be able to take part in a research study looking at how drugs used to treat multiple myeloma work.

Do you have Neuroblastoma or Osteosarcoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Researchers are studying different doses of a therapy (CD19 CAR T-cells) to find the dose that is both the most effective and the safest for patients with relapsed or refractory B-cell lymphoma.

At the UNC At the Center of Excellence for Eating Disorders, our mission is to better understand the causes and consequences of eating disorders in order to develop better treatment options. In pursuit of this mission, we conduct several research studies each year. To conduct these research studies, we need help from volunteers - individuals who want to help us better understand eating disorders. You can help by volunteering to join our research registry. Anyone can join our registry. We welcome volunteers with no history of an eating disorder, as well as volunteers with a current or past history of an eating disorder.

Are you or someone you know related to an adult or child with Type 1 Diabetes? If so, you may eligible to participate in TrialNet.

The participant registry will assist with study recruitment for current and future studies at the UNC-CH Adams School of Dentistry.

The purpose of this study is to establish a safe dose of study cells (ATLCAR.CD30.CCR4 and ATLCAR.CD30) to give to patients with CD30+ refractory/relapsed Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.